Clean Science Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹299 Cr +22% YoYSee revenue, profit and what management said. You are viewing Q3 FY26.
CS

Clean Science

Q3 FY26Chemicals & Petrochemicals

Clean Science Q3 FY26 earnings call: Revenue & Margins

Q3 FY26 earnings call: what management said on revenue, margins and capex.

Revenue
₹220Cr
−8.7% YoY
−10.2% QoQ
Net profit
₹46Cr
−30.3% YoY
−16.4% QoQ
Margin
33%
−8 pp YoY
−3 pp QoQ
Price₹822
Market cap₹8.8K Cr
P/E37.7

The short version

Performance Chemical 1 plant started producing in-house hydroquinone and catechol; sales to start from February with growth expected in March FY '27. The company anticipates margin improvement and revenue growth by launching new products and maintaining disciplined capex cycles.

From Clean Science's Q3 FY26 earnings-call transcript · updated 26 Aug 2026.

Revenue & Sales Performance

  • Performance Chemical 1 plant started producing in-house hydroquinone and catechol; sales to start from February with growth expected in March FY '27.
  • Performance Chemical 2 plant commissioning delayed to May-June FY '27; revenue generation anticipated from Q4 FY '27.
  • HALS business showing strong growth, with 55% Y-o-Y volume increase; expected to sustain momentum in coming years.
  • New product commercialization (hydroquinone and catechol) will lower raw material costs and enhance margins.
  • Efforts ongoing to improve process efficiencies and bring more products online, aiming for volume growth and margin improvement.
  • Domestic and international demand expected to recover post current macroeconomic challenges.
  • Trade deal with Europe starting in FY '27 to potentially reduce tariffs (5.5%-12%), helping competitiveness against China.

2 more points from Clean Science's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Clean Science said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Hydroquinone and catechol plants were commercialized in December; customer trials ongoing.
  • Capex for Performance Chemical 2 is on plan; commercialization expected in Q1 FY '27 (around May-June).
  • Performance Chemical 2 will start generating staggered revenues from Q4 FY '27.
  • Performance Chemical 1 running at ~80% capacity utilization; expected revenue INR 260 crores in FY '27 (down from earlier estimate of INR 320 crores) due to reduced prices.
  • Capex investments amount to around INR 1.5 billion each for Performance Chemical 1 and 2.
  • The expansion of TBHQ and in-house production of hydroquinone expected to moderate raw material costs and improve margins.

2 more points from Clean Science's call on capex

Create a free account to keep reading this call

Top-ranked in Chemicals & Petrochemicals

Ranked on what management guided this quarter

Guidance-ranked
2Shiv Texchem
Rev 1Mar 2
3
Rev 1Mar 3
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Clean Science said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

See what Clean Science said on order book & pipeline — free account, 30 seconds.

Clean Science — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Clean Science Q3 FY26 results — key figures

Clean Science Q3 FY26 reported results vs Q3 FY25, ₹ crore
₹ CrQ3 FY26Q3 FY25YoYQ2 FY26QoQ
Revenue220241-8.7%245-10.2%
Operating profit (EBITDA)7298-26.5%87-17.2%
Operating margin33%41%-8 pp36%-3 pp
Profit before tax6385-25.9%75-16%
Net profit (PAT)4666-30.3%55-16.4%
EPS (₹)4.326.18-30.1%5.22-17.2%

Source: reported quarterly figures (Screener), ₹ crore.

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹299 Cr, net profit ₹56 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

Others in Chemicals & Petrochemicals this season

  • Neochem Bio (Q3 FY26)

    Revenue for Q2 FY26 (Sept’25) stood at ₹4,583.16 Lakh. Key investor presentation takeaways from Neochem Bio Solutions Ltd's Q3 FY26 investor presentation — and

  • Thirumalai Chemicals (Q3 FY26)

    Q3 FY26 Revenue from Operations (INR Cr):** . Key investor presentation takeaways from Thirumalai Chemicals Ltd's Q3 FY26 investor presentation — and how it ran

  • IVP (Q3 FY26)

    Q3 FY26 Revenue from Operations: ₹144.97 crore . Key investor presentation takeaways from IVP's Q3 FY26 investor presentation — and how it ranks against sector

  • Gujarat Alkalies (Q3 FY26)

    3,144.48 Crores, down from Rs. Key investor presentation takeaways from Gujarat Alkalies & Chemicals Ltd's Q3 FY26 investor presentation — and how it ranks agai

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Clean Science and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Clean Science Q3 FY26 results?

Performance Chemical 1 plant started producing in-house hydroquinone and catechol; sales to start from February with growth expected in March FY '27. The company anticipates margin improvement and revenue growth by launching new products and maintaining disciplined capex cycles.

What is Clean Science share price analysis?

Clean Science currently shows a neutral. The stock trades at a P/E of 37.7 with a market cap of ₹8,774 Cr. Investors should review the full earnings analysis for detailed insights.

Is Clean Science planning capital expenditure?

Hydroquinone and catechol plants were commercialized in December; customer trials ongoing.

Keep Clean Science on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.